PHASE Scientific Expands INDICAID® Respiratory Portfolio with Exclusive U.S. Launch of Novel FebriDx® Test
Introduction of FebriDx will enhance PHASE Scientific's INDICAID® portfolio and strengthen its leadership in point-of-care respiratory diagnostics.
Partnership underscores PHASE Scientific's proven commercial execution in the U.S. market with its extensive nationwide clinical network, building upon its strengths in R&D innovation.
GARDEN GROVE, Calif., July 15, 2025 /PRNewswire/ -- PHASE Scientific, a fast-growing biotech company known for its science-driven innovation and commitment to improving healthcare outcomes, today announced that it has entered into an exclusive U.S. distribution agreement with Lumos Diagnostics for FebriDx®, a rapid point-of-care (POC) test that aids in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology in approximately 10 minutes using a single drop of blood.
With strong product differentiation, FDA 510(k) clearance, and an anticipated CLIA waiver application within the next three months, FebriDx® is poised to transform how clinicians diagnose and manage respiratory infection.
FebriDx® will become part of PHASE Scientific's INDICAID® portfolio – a trusted brand for high-quality, accessible rapid diagnostics. The partnership marks a significant milestone in PHASE's commercial expansion in the United States, building upon a nationwide network of urgent care centers, clinics, and healthcare providers and a proven track record of distributing over 100 million INDICAID® tests.
"We are thrilled to partner with Lumos, a company that shares our commitment to shaping the future of healthcare through innovation and collaboration, and support them with our scalable go-to-market strength in North America," said Dr. Ricky Chiu, Founder and CEO of PHASE Scientific. "A powerful complement to our INDICAID® respiratory portfolio, FebriDx® is a first-in-class diagnostic that perfectly aligns with our mission to bring fast, actionable diagnostics to the frontlines of care. We are confident this will unlock synergistic opportunities, further advancing our impact on antimicrobial stewardship and clinical decision-making across the U.S. As we continue to expand the INDICAID® brand, we remain dedicated to strengthening our leadership in point-of-care solutions, empowering clinicians, and improving access to high-quality healthcare."
Doug Ward, CEO of Lumos Diagnostics, commented, "This distribution agreement reflects a pivotal moment in Lumos' evolution. We look forward to working with the PHASE Scientific team to ensure that FebriDx® secures adoption in the U.S. market, delivering tangible clinical and financial value to the broader healthcare system. This agreement also validates the value of the FebriDx® technology and provides a clear pathway to the U.S. market, which we expect will accelerate rapidly should we receive a grant for CLIA waiver from the FDA.
Transforming Respiratory Infection Diagnosis
FebriDx® fills this diagnostic gap with a rapid, point-of-care test that uses a unique combination of C-reactive protein (CRP) and Myxovirus resistance protein A (MxA) biomarkers to aid in the diagnosis of bacterial from non-bacterial respiratory infections after 10 minutes. Its lateral flow format requires only a fingerstick blood sample and has been validated in a pivotal clinical study and demonstrated good diagnostic performance that can, in turn, improve diagnostic confidence and antibiotic stewardship decisions.
By enabling faster, more informed treatment decisions, FebriDx® supports more targeted care in busy patient settings – currently including urgent and emergency care. A CLIA waiver study is progressing well, with anticipated study completion and application submission expected within the next three months. This would expand access to FebriDx® across a broader range of outpatient environments, representing a market opportunity of approximately US$1.5 billion.
Driving Antimicrobial Stewardship
FebriDx® plays a critical role in aiding in addressing the global threat of antimicrobial resistance (AMR), which continues to strain public health systems and drive avoidable costs. By providing rapid, actionable results at the point of care, FebriDx® helps reduce unnecessary antibiotic prescribing – a key contributor to AMR – and improves clinical workflows by supporting more accurate triage and treatment.
Clinical studies have demonstrated that integrating FebriDx® can lead to reduced antibiotic use, lower healthcare costs, and better patient outcomes. Its unique ability to guide appropriate prescribing makes it a valuable tool in everyday patient care.
Strengthening U.S. Market Presence
This agreement represents a major step in PHASE Scientific's strategy to reinforce its dual strengths in R&D innovation and commercial execution, as well as accelerate its leadership in the U.S. diagnostics market. Known for its proprietary PHASIFY™ technology and innovation pipeline in cancer and infectious disease diagnostics, PHASE Scientific is now demonstrating its scalable go-to-market strength in North America.
About PHASE Scientific
PHASE Scientific International Limited ("PHASE Scientific") is a fast-growing biotech company with a mission to inspire a new state of health through innovative diagnostics and healthcare solutions. With operations in the U.S., mainland China, and Hong Kong SAR, PHASE delivers novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies, empowering better disease detection, diagnosis, and management.
PHASE Scientific's products and services have received certifications from the U.S. Food and Drug Administration (FDA), the European Union CE, and regulatory agencies in various countries, providing over 100 million testing products and services in more than 30 countries worldwide.
PHASE Scientific has recently completed a US$34 million Series A funding round, representing the largest Series A raise in Asia's diagnostic technology sector since 2019. Other supporters include Gates Foundation, and US governmental agencies National Science Foundation and National Institutes of Health. For more information, please visit phasescientific.com.
About FebriDx®
FebriDx® is a unique, rapid point of care test that helps clinicians differentiate between bacterial and non-bacterial acute respiratory infections through a simple fingerstick blood sample after 10 minutes.
By aiding clinicians make faster, better decisions at the point-of-care, FebriDx® has the potential to improve patient outcomes, reduce unnecessary antibiotic prescriptions, and lower overall healthcare costs – all while addressing the urgent global challenge of antimicrobial resistance (AMR).
About Lumos Diagnostics
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.
For more information visit lumosdiagnostics.com.
Media Contact
PHASE Scientificpr@phasesci.com
FGS GlobalPhaseSci@fgsglobal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/phase-scientific-expands-indicaid-respiratory-portfolio-with-exclusive-us-launch-of-novel-febridx-test-302506187.html
SOURCE PHASE Scientific
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 minutes ago
- Associated Press
Tennessee readies for execution of man with working implanted defibrillator
NASHVILLE, Tenn. (AP) — Tennessee is gearing up for an execution on Tuesday that experts say would likely mark the first time a man has been put to death with a working defibrillator in his chest. Gov. Bill Lee declined Monday to grant a reprieve, clearing the way for Byron Black's execution after a legal battle and ongoing uncertainty about whether the implantable cardioverter-defibrillator will shock his heart when the lethal drug takes effect. The nonprofit Death Penalty Information Center said it's unaware of any other cases in which a person on death row made similar claims to Black's about defibrillators or pacemakers. Black's attorneys said they haven't found a comparable case, either. Lee said the courts have 'universally determined that it is lawful to carry out the jury's sentence of execution given to Mr. Black for the heinous murders of Angela Clay and her daughters Lakeisha, age 6, and Latoya, age 9.' The U.S. Supreme Court on Monday rejected Black's appeals. The execution would be Tennessee's second since May, after a pause for five years, first because of COVID-19 and then because of missteps by state corrections officials. Twenty-seven men have died by court-ordered execution so far this year in the U.S., and nine other people are scheduled to be put to death in seven states during the remainder of 2025. The number of executions this year exceeds the 25 carried out last year and in 2018. It is the highest total since 2015, when 28 people were put to death. Black's condition Black, 69, is in a wheelchair, and he has dementia, brain damage, kidney failure, congestive heart failure and other conditions, his attorneys have said. The implantable cardioverter-defibrillator he has is a small, battery-powered electronic device that is surgically implanted in the chest. It serves as a pacemaker and an emergency defibrillator. Black's attorneys say in order to be sure it's off, a doctor must place a programming device over the implant site, sending it a deactivation command, with no surgery required. In mid-July, a trial court judge agreed with Black's attorneys that officials must have his device deactivated to avert the risk that it could cause unnecessary pain and prolong the execution. But the state Supreme Court intervened July 31 to overturn that decision, saying the other judge lacked the authority to order the change. The state has disputed that the lethal injection would cause Black's defibrillator to shock him. Even if shocks were triggered, Black wouldn't feel them, the state said. Black's attorneys have countered that even if the lethal drug being used, pentobarbital, renders someone unresponsive, they aren't necessarily unaware or unable to feel pain. Kelley Henry, Black's attorney, said the execution could become a 'grotesque spectacle.' The legal case also spurred a reminder that most medical professionals consider participation in executions a violation of health care ethics. Black's case Black was convicted in the 1988 shooting deaths of his girlfriend Angela Clay, 29, and her two daughters. Prosecutors said he was in a jealous rage when he shot the three at their home. At the time, Black was on work-release while serving time for shooting Clay's estranged husband. Linette Bell, whose sister and two nieces were killed, recently told WKRN-TV: 'He didn't have mercy on them, so why should we have mercy on him?' Intellectual disability claim In recent years, Black's legal team has unsuccessfully tried to get a new hearing over whether he is intellectually disabled and ineligible for the death penalty under U.S. Supreme Court precedent. His attorneys have said that if they had delayed a prior attempt to seek his intellectual disability claim, he would have been spared under a 2021 state law. Nashville District Attorney Glenn Funk contended in 2022 that Black is intellectually disabled and deserved a hearing under that 2021 law, but the judge denied it. That is because the 2021 law denies a hearing to people on death row who have already filed a similar request and a court has ruled on it 'on the merits.' In Funk's attempt, he focused on input from an expert for the state in 2004 who determined back then that Black didn't meet the criteria for what was then called 'mental retardation.' But she concluded that Black met the new law's criteria for a diagnosis of intellectual disability. Black also sought a determination by the courts that he is incompetent to be executed.
CBS News
2 minutes ago
- CBS News
Minnetrista mom of 3 uses data and science through Edina lab to improve her life
The beginning of August is peak training season for the Twin Cities Marathon. One participant of this year's race is a mom of three from Minnetrista, Minnesota, who is taking extra steps to make sure she's running her best and in the safest way. "I had my third baby. I wasn't feeling good," said Valerie Vadnais Wall. "I was tired all the time taking care of everybody else and not myself." She's been running for the last 10 years, and has seen huge improvement in her health. "I've lost 65 pounds," said Vadnais Wall. She loved running so much that she joined a group of women in the Chaska/Chanhassen community to keep her motivated. "I decided that I want to have fun and join something that is empowering, and it was Mom's On The Run," said Vadnais Wall. Now, she's preparing for her fourth marathon, which is taking place in the Twin Cities, and has decided to take her training to the next level. As a dentist who co-owns a practice, she believes in the science and importance of data. "I don't want to succumb to the health diseases, like diabetes, high blood pressure. My mom has dementia, and I didn't want that for myself, so I wanted to take the power to have the data and then to do better," said Vadnais Wall, who came to Kelly McKenzie at the Human Powered Health lab in Edina, Minnesota. "It's nice to have data to validate what you're doing is working for you," said McKenzie. At the lab, McKenzie measures her oxygen levels, heart rate, bone strength and balance. "For her going into premenopause, and then menopause eventually, you want to make sure that your bone is in a really healthy spot, so that when your estrogen starts to decrease, your bone will naturally go with it," said McKenzie. This type of testing is not reserved for elite athletes. It's recommended for everyone seeking to further their knowledge on their health and well-being. "I'm not a professional athlete, so it's a little intimidating, but [Kelly] made it super easy and comfortable, and I'm excited to know that all this hard work is paying off," said Vadnais Wall. This type of testing will help Vadnais Wall with basic things outside of running, like lifting groceries and walking up stairs, to avoid any injuries. "I do feel that, at 51, I'm in the best shape of my life, even after my 20s and 30s, so I'm excited," said Vadnais Wall. "I do want to be that role model to other people, to other women who are middle-aged." Vadnais Wall will be running the Twin Cities Marathon on Oct. 5 with her kids cheering her on along the course.
CBS News
2 minutes ago
- CBS News
Beloved Downtown Home and Garden store in Ann Arbor closing its doors
One of Ann Arbor, Michigan's most cherished landmarks is preparing to say goodbye. Downtown Home & Garden, a beloved staple in the community for generations, has announced it will close its doors for good on Christmas Eve. The historic store, nestled at the corner of Ashley and Liberty streets, has long been more than just a place to shop. It's been a gathering space, a hub for local gardeners and foodies, and a symbol of Ann Arbor's unique charm. But after weathering countless challenges over the decades, the financial burden has become too heavy to bear. "I hate to beat the Covid drum but the best way I can describe it is if that was an earthquake we're still having aftershocks and I think that you know, even if you feel like you get a little ground underneath you and something else kind of rattle it so I think people's ability to Have the capacity for uncertainty is kind of limited just because of the things that we've all been through together in the previous years," said owner Kelly Vore. In a heartfelt message shared with the community, the owner cited ongoing financial strain as the reason for the closure. The store has fought to stay afloat through the COVID-19 pandemic, supply chain disruptions, and, more recently, increased rent. A planned lease renewal this year came with a 26% increase, with another hike already on the horizon. As the countdown to Christmas Eve begins, Downtown Home & Garden is focusing on making its final months meaningful. Progressive markdowns on merchandise are already underway, and the team is hoping for a strong holiday season to help close out their legacy on a high note. The store will remain open daily until its final day, with staff ready to assist customers, reminisce with longtime patrons, and celebrate the remarkable journey that spans more than 100 years. "We are here and committed through Christmas Eve. My crew and I are dedicated to bringing this recognizable and lovely experience that everyone is used to having from us. Whether it's pumpkins and moms and tulip bulbs and amaryllis bulbs and Christmas trees and all of those things, that's our plan to deliver on all of that and be as awesome as we always are."
